Johnson and Johnson's Posson Tatterser gets NMPA approval to treat pulmonary hypertension in children
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Johnson and Johnson's JanssenPharmaceutical(http://company(http://Actelion announced that Posson tatters (full-®, English brand name: Tracleer, generic name: bosentan) (spec: 32mg) was approved by China's NationalPharmaceutical(http://Regulatory Authority (NMPA) for the treatment of children's pulmonary hypertension (PAH)Posintan dispersion tablets (all-ali ®) thus became the first approved children with pulmonary hypertension in the countryabout Tracleer
Tracleer, an oral lyptin receptor antagonist (ERA), was launched in 2001 as the first approved PAH treatmentdrug(http://and is currently approved by several countries around the worldIn the U.S., Tracleer 32mg dispersal tablets were approved by theFDA(http://in September 2017, featuring a cartic tablet that can be scattered in a teaspoon of water and then taken orallyThe low-dose and kerated design of Tracleer's new tablets allows doctors toprescription(http://based on the weight adjustment of PAH pediatric patientsTracleer is an oral ERA that works by blocking the effects of extra endothelialin, a naturally occurring chemical in the body that involves blood flowHowever, endothelial levels in PAH patients are higher than normalStudies have found that too much endothelial softens blood vessels, making it more difficult for blood to flow through the constricted blood vessels, which can affect the normal functioning of the heart
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
